Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 122

Sort by

Sort Order Select

Journal Articles

T/NK Cell-Associated Transcriptomic Profile Informs Response to FLT3 Inhibitors in Acute Myeloid Leukemia

Blood (2024) 144 (Supplement 1): 2916.

https://doi.org/10.1182/blood-2024-205994

Published: 2024

Journal Articles

Methodology and Clinical Significance of Longitudinal UBA1 Clonal Burden Evaluation in Vexas Syndrome

Blood (2024) 144 (Supplement 1): 2690.

https://doi.org/10.1182/blood-2024-194413

Published: 2024

Journal Articles

A Molecular-Based Ecosystem to Improve Personalized Medicine in Patients with Chronic Myelomonocytic Leukemia (CMML)

Luca Lanino, Anthony M. Hunter, Nico Gagelmann, Marie Robin, Claudia Sala, Daniele Dall'Olio, Carmelo Gurnari, Lorenzo Dall'Olio, Yu-Hung Wang, Lisa Pleyer, Blanca Xicoy, Guillermo Montalban-Bravo, Lee-Yung Shih, Tamanna Haque, Omar Abdel-Wahab, Klaus Geissler, Alex Bataller, Alexandre Bazinet, Manja Meggendorfer, Ilaria Carola Casetti, Elisabetta Sauta, Erica Travaglino, Laura Palomo, Lurdes Zamora, David Quintela, Andres Jerez, Elena Cornejo, Paloma Garcia Martin, Marina Díaz-Beyá, Alejandro Avendaño Pita, Veronica Roldan, Dolly Viviana Fiallo Suarez, Estefania Cerezo Velasco, Marisa Calabuig, Esperanza Such, Guillermo Sanz, Anne Sophie Kubasch, Cristina Castilla-Llorente, Claude-Éric Bulabois, Laetitia Souchet, Hussein Awada, Massimo Bernardi, Patrizia Chiusolo, Antonio Curti, Luisa Giaccone, Francesco Onida, Lorenza Maria Borin, Francesco Passamonti, Elisa Diral, Vladan Vucinic, Gregorio Maria Bergonzi, Maria Teresa Voso, Hsin-An Hou, Wen-Chien Chou, Chi-Yuan Yao, Chien-Chin Lin, Hwei-Fang Tien, Alessia Campagna, Marta Ubezio, Antonio Russo, Gabriele Todisco, Giulia Maggioni, Cristina Astrid Tentori, Alessandro Buizza, Gianluca Asti, Matteo Zampini, Elena Riva, Mattia Delleani, Angela Consagra, Francesca Ficara, Armando Santoro, Luciana Carota, Tiziana Sanavia, Cesare Rollo, Ahmad Kiwan, Jennifer VanOudenhove, Piero Fariselli, Najla H. Al Ali, David Sallman, Wolfgang Kern, Guillermo Garcia-Manero, Swapna Thota, Elizabeth A. Griffiths, Matilde Yung Follo, Carlo Finelli, Uwe Platzbecker, Francesc Sole, Maria Diez-Campelo, Jaroslaw Maciejewski, Rafael Bejar, Felicitas R. Thol, Nicolaus Kröger, Pierre Fenaux, Raphael Itzykson, Timothy Aaron Graubert, Michaela Fontenay, Amer M. Zeidan, Rami S. Komrokji, Valeria Santini, Torsten Haferlach, Ulrich Germing, Saverio D'Amico, Gastone Castellani, Mrinal M. Patnaik, Eric Solary, Eric Padron, Matteo Giovanni Della Porta

Blood (2024) 144 (Supplement 1): 1003.

https://doi.org/10.1182/blood-2024-200104

Published: 2024

Journal Articles

Venetoclax and Azacitidine for Relapse Prevention in NPM1 -Mutated Acute Myeloid Leukemia in Molecular Failure: Results from the Ongoing Gimema AML2521 Phase 2 Trial

Blood (2024) 144 (Supplement 1): 2893.

https://doi.org/10.1182/blood-2024-210315

Published: 2024

Journal Articles

Survival Analysis of Gimema AML1718, a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia

Blood (2024) 144 (Supplement 1): 2891.

https://doi.org/10.1182/blood-2024-207842

Published: 2024

Journal Articles

Myeloid Differentiation in Myelodysplastic Neoplasms and Leukemic Cells: Role of Azacitidine and Direct Contact with Mesenchymal Stromal Cells

Eleonora Ceneri, Irene Casalin, Alessia De Stefano, Alessandra Cappellini, Lucio Cocco, Stefano Ratti, Lucia Manzoli, Michele Cavo, Miriam Fogli, Sarah Parisi, Stefania Paolini, Marilena Ciciarello, Antonio Curti, Carlo Finelli, Matilde Yung Follo

Blood (2024) 144 (Supplement 1): 6688.

https://doi.org/10.1182/blood-2024-204876

Published: 2024

Journal Articles

Interferon-Gamma Production By Dysplastic Cells Supports an Immune-Tolerant Bone Marrow Microenvironment in Myelodysplastic Syndrome Patients

Marilena Ciciarello, Francesca Girotti, Darina Ocadlikova, Letizia Zannoni, Federica Ardizzoia, Cecilia Evangelisti, Cesare Rossi, Michele Cavo, Antonio Curti

Blood (2024) 144 (Supplement 1): 6687.

https://doi.org/10.1182/blood-2024-203447

Published: 2024

Journal Articles

Investigating Phosphoinositide-Related and Apoptotic Pathways in Azacitidine and Venetoclax Combination Therapy in Higher-Risk Myelodysplastic Neoplasms and Leukemic Cell Lines

Irene Casalin, Eleonora Ceneri, Alessia De Stefano, Alessandra Cappellini, Andrea Pellagatti, Jacqueline Boultwood, Michele Cavo, Stefano Ratti, Lucia Manzoli, Lucio Cocco, Anna Ferrari, Giorgia Simonetti, Giovanni Martinelli, Miriam Fogli, Stefania Paolini, Sarah Parisi, Antonio Curti, Carlo Finelli, Matilde Yung Follo

Blood (2024) 144 (Supplement 1): 6686.

https://doi.org/10.1182/blood-2024-200842

Published: 2024

Journal Articles

Absolute Lymphocyte Count As a Novel Prognostic Predictor Compared to Minimal Residual Disease and Molecular Status in Patients with Acute Myeloid Leukemiatreated with Intensive Chemotherapy

Gianluca Cristiano, Jacopo Nanni, Letizia Zannoni, Federico Zingarelli, Federica Ardizzoia, Chiara Sartor, Sarah Parisi, Stefania Paolini, Cristina Papayannidis, Michele Cavo, Antonio Curti

Blood (2024) 144 (Supplement 1): 6116.

https://doi.org/10.1182/blood-2024-209333

Published: 2024

Journal Articles

Association of Hypometilating Agents (HMA) + Venetoclax (VEN) in the Therapy of Acute Myeloid Leukemias Evolved from Myelodysplastic Syndromes (AML-MDS) Already Treated with Azacytidine

Blood (2023) 142 (Supplement 1): 6497.

https://doi.org/10.1182/blood-2023-186085

Published: 2023

Journal Articles

Association of Hypomethylating Agents + Venetoclax in the Real-Life Treatment of Myeloproliferative Neoplasms in Blastic Phase

Blood (2023) 142 (Supplement 1): 1842.

https://doi.org/10.1182/blood-2023-190091

Published: 2023

Journal Articles

Iron-Related Laboratory Profile May Predict Response and MRD Negativity Rate in Acute Myeloid Leukemia Patients

Federico Zingarelli, Gianluca Cristiano, Chiara Sartor, Letizia Zannoni, Jacopo Nanni, Martina Barone, Lorenza Bandini, Emanuela Ottaviani, Valentina Robustelli, Nicoletta Testoni, Mario Arpinati, Cristina Papayannidis, Michele Cavo, Antonio Curti

Blood (2023) 142 (Supplement 1): 6052.

https://doi.org/10.1182/blood-2023-188709

Published: 2023

Journal Articles

Bone Marrow Microenvironment As a Potential Key Regulator of Hematopoietic Cells Stemness in Myelodysplastic Syndromes (MDS)

Irene Casalin, Alessia De Stefano, Alessandra Cappellini, Eleonora Ceneri, Martina Lops, Andrea Pellagatti, Jacqueline Boultwood, Michele Cavo, Stefano Ratti, Lucia Manzoli, Lucio Cocco, Marilena Ciciarello, Miriam Fogli, Stefania Paolini, Sarah Parisi, Antonio Curti, Carlo Finelli, Matilde Yung Follo

Blood (2023) 142 (Supplement 1): 6463.

https://doi.org/10.1182/blood-2023-179914

Published: 2023

Journal Articles

T Cell/Natural Killer (NK) Cell Transcriptional Profiles Are Associated with Response to Gilteritinib in FLT3 -Mutated Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 2947.

https://doi.org/10.1182/blood-2023-184741

Published: 2023

Journal Articles

Real World Outcome of Unfit Patients with Acute Myeloid Leukemia Treated with the Combination Venetoclax Plus Hypomethylating Agents in the Gimema AML2320 Observational Trial

Blood (2023) 142 (Supplement 1): 1514.

https://doi.org/10.1182/blood-2023-178505

Published: 2023

Journal Articles

Phase II Study on Venetoclax (Ven) Plus Decitabine (Dec) (Ven-Dec) for Elderly (≥60 <75years) Patients with Newly Diagnosed High-Intermediate Risk Acute Myeloid Leukemia (AML) Elegible for Allogeneic Stem Cell Transplantation: Final Report of Ven DEC GITMO Study

Blood (2023) 142 (Supplement 1): 1513.

https://doi.org/10.1182/blood-2023-185045

Published: 2023

Journal Articles

Single-Cell Metabolic Profiling Integrated with Extracellular Vesicle Analysis Reveals Novel Metabolic Vulnerabilities and Prognostic Biomarkers in Acute Myeloid Leukemia

Dorian Forte, Filippo Maltoni, Samantha Bruno, Paulina Garcia-Gonzalez, Gianluca Cristiano, Chiara Sartor, Simona Soverini, Lucia Catani, Rafael José Argüello, Michele Cavo, Antonio Curti

Blood (2023) 142 (Supplement 1): 1598.

https://doi.org/10.1182/blood-2023-185909

Published: 2023

Journal Articles

Final Analysis for the Primary End-Point of Gimema AML1718, a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 1536.

https://doi.org/10.1182/blood-2023-184678

Published: 2023

Journal Articles

Safety and Tolerability of AZD0466 As Monotherapy for Patients with Advanced Hematologic Malignancies. Results from a Phase I/II Trial

Blood (2023) 142 (Supplement 1): 5907.

https://doi.org/10.1182/blood-2023-179168

Published: 2023

Journal Articles

Single Agent Tagraxofusp in Relapsed/Refractory CD123-Positive Acute Myeloid Leukemia: A Preliminary Analysis of Italian Gimema AML2020 Trial

Blood (2023) 142 (Supplement 1): 2918.

https://doi.org/10.1182/blood-2023-189417

Published: 2023

NARROW

T/NK Cell-Associated Transcriptomic Profile Informs Response to FLT3 Inhibitors in Acute Myeloid Leukemia

Methodology and Clinical Significance of Longitudinal UBA1 Clonal Burden Evaluation in Vexas Syndrome

A Molecular-Based Ecosystem to Improve Personalized Medicine in Patients with Chronic Myelomonocytic Leukemia (CMML)

Venetoclax and Azacitidine for Relapse Prevention in NPM1 -Mutated Acute Myeloid Leukemia in Molecular Failure: Results from the Ongoing Gimema AML2521 Phase 2 Trial

Survival Analysis of Gimema AML1718, a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia

Myeloid Differentiation in Myelodysplastic Neoplasms and Leukemic Cells: Role of Azacitidine and Direct Contact with Mesenchymal Stromal Cells

Interferon-Gamma Production By Dysplastic Cells Supports an Immune-Tolerant Bone Marrow Microenvironment in Myelodysplastic Syndrome Patients

Investigating Phosphoinositide-Related and Apoptotic Pathways in Azacitidine and Venetoclax Combination Therapy in Higher-Risk Myelodysplastic Neoplasms and Leukemic Cell Lines

Absolute Lymphocyte Count As a Novel Prognostic Predictor Compared to Minimal Residual Disease and Molecular Status in Patients with Acute Myeloid Leukemiatreated with Intensive Chemotherapy

Association of Hypometilating Agents (HMA) + Venetoclax (VEN) in the Therapy of Acute Myeloid Leukemias Evolved from Myelodysplastic Syndromes (AML-MDS) Already Treated with Azacytidine

Association of Hypomethylating Agents + Venetoclax in the Real-Life Treatment of Myeloproliferative Neoplasms in Blastic Phase

Iron-Related Laboratory Profile May Predict Response and MRD Negativity Rate in Acute Myeloid Leukemia Patients

Bone Marrow Microenvironment As a Potential Key Regulator of Hematopoietic Cells Stemness in Myelodysplastic Syndromes (MDS)

T Cell/Natural Killer (NK) Cell Transcriptional Profiles Are Associated with Response to Gilteritinib in FLT3 -Mutated Acute Myeloid Leukemia

Real World Outcome of Unfit Patients with Acute Myeloid Leukemia Treated with the Combination Venetoclax Plus Hypomethylating Agents in the Gimema AML2320 Observational Trial

Phase II Study on Venetoclax (Ven) Plus Decitabine (Dec) (Ven-Dec) for Elderly (≥60 <75years) Patients with Newly Diagnosed High-Intermediate Risk Acute Myeloid Leukemia (AML) Elegible for Allogeneic Stem Cell Transplantation: Final Report of Ven DEC GITMO Study

Single-Cell Metabolic Profiling Integrated with Extracellular Vesicle Analysis Reveals Novel Metabolic Vulnerabilities and Prognostic Biomarkers in Acute Myeloid Leukemia

Final Analysis for the Primary End-Point of Gimema AML1718, a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia

Safety and Tolerability of AZD0466 As Monotherapy for Patients with Advanced Hematologic Malignancies. Results from a Phase I/II Trial

Single Agent Tagraxofusp in Relapsed/Refractory CD123-Positive Acute Myeloid Leukemia: A Preliminary Analysis of Italian Gimema AML2020 Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only